肝细胞癌对三氧化二砷的化疗耐药性机制

国际肿瘤学杂志››2016,Vol. 43››Issue (11): 861-864.doi:10.3760/cma.j.issn.1673-422X.2016.11.016

肝细胞癌对三氧化二砷的化疗耐药性机制

陈耀庭，胡晓俊，李丹，单鸿

519000 珠海，中山大学附属第五医院介入医学中心（陈耀庭、单鸿）；中山大学孙逸仙纪念医院介入放射科（陈耀庭）；中山大学介入放射学研究所（胡晓俊、李丹、单鸿）

收稿日期:2016-03-28出版日期:2016-11-08发布日期:2016-11-02
通讯作者:单鸿，Email: shanhong@mail.sysu.edu.cn E-mail:shanhong@mail.sysu.edu.cn
基金资助:

国家自然科学基金（81430041）

Chemotherapy drug resistance mechanisms of hepatocellular carcinoma to arsenic trioxide

Chen Yaoting, Hu Xiaojun, Li Dan, Shan Hong

Center for Interventional Medicine, Fifth Affiliated Hospital of Sun Yatsen University, Zhuhai 519000, China; Department of Interventional Radiology, Sun Yatsen Memorial Hospital, Sun Yatsen University, Guangzhou 510120, China

Received:2016-03-28Online:2016-11-08Published:2016-11-02
Contact:Shan Hong E-mail:shanhong@mail.sysu.edu.cn
Supported by:

National Natural Science Foundation of China (81430041)

摘要/Abstract

摘要：研究证实三氧化二砷（As2O3）单药治疗肝细胞癌（HCC）的效果有限，多数学者认为主要与HCC的化疗耐药有关。HCC对As2O3的耐药机制目前仍很不明确，研究显示与As2O3的代谢特点、肝癌组织学和分子生物学的特征等密切相关。

陈耀庭，胡晓俊，李丹，单鸿. 肝细胞癌对三氧化二砷的化疗耐药性机制[J]. 国际肿瘤学杂志, 2016, 43(11): 861-864.

Chen Yaoting, Hu Xiaojun, Li Dan, Shan Hong. Chemotherapy drug resistance mechanisms of hepatocellular carcinoma to arsenic trioxide[J]. Journal of International Oncology, 2016, 43(11): 861-864.

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, doubleblind, placebocontrolled trial［J］. Lancet Oncol, 2015, 16(13): 1344-1354. DOI: 10.1016/S14702045(15) 001989. ［3］ de The H, Le Bras M, LallemandBreitenbach V. The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies［J］. J Cell Biol, 2012, 198(1): 11-21. DOI: 10.1083/jcb.201112044. ［4］ Emadi A, Gore SD. Arsenic trioxidean old drug rediscovered［J］. Blood Rev, 2010, 24(45): 191199. DOI: 10.1016/j.blre.2010.04.001. ［5］ Zhang X, Yang XR, Sun C, et al. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma［J］. Cancer Lett, 2015, 366(1): 112122. DOI: 10.1016/j.canlet.2015.06.014. ［6］ Zheng T, Yin D, Lu Z, et al. Nutlin3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in hepatocellular carcinoma［J］. Mol Cancer, 2014, 13(5): 133-144. DOI: 10.1186/1476-4598-13-133. ［7］ Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo［J］. Adv Drug Deliv Rev, 2013, 65(1): 71-79. DOI: 10.1016/j.addr.2012.10.002. ［8］ Hua H, Qin S, Rui J, et al. Pharmacokinetics of arsenic trioxide (As(2)O(3)) in Chinese primary hepatocarcinoma patients［J］. Asian Pac J Cancer Prev, 2011, 12(1): 61-65. DOI:http://dx.doi.org/10.7314/APJCP.2011.12.1.61. ［9］ Ahn RW, Chen F, Chen H, et al. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer［J］. Clin Cancer Res, 2010, 16(14): 3607-3617. DOI: 10.1158/1078-0432.CCR-10-0068. ［10］ Qian C, Wang Y, Chen Y, et al. Suppression of pancreatic tumor growth by targeted arsenic delivery with antiCD44v6 single chain antibody conjugated nanoparticles［J］. Biomaterials, 2013, 34(26): 6175-6184. DOI: 10.1016/j.biomaterials.2013.04.056. ［11］ Wilson GK, Tennant DA, McKeating JA. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions［J］. J Hepatol, 2014, 61(6): 13971406. DOI: 10.1016/j.jhep.2014.08.025. ［12］ Warfel NA, ElDeiry WS. HIF1 signaling in drug resistance to chemotherapy［J］. Curr Med Chem, 2014, 21(26): 3021-3028. DOI: 10.2174/0929867321666140414101056. ［13］ Poller B, Wagenaar E, Tang SC, et al. Doubletransduced MDCKⅡ cells to study human Pglycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the bloodbrain barrier［J］. Mol Pharm, 2011, 8(2): 571-582. DOI: 10.1021/mp1003898. ［14］ Cao Y, Eble JM, Moon E, et al. Tumor cells upregulate normoxic HIF1alpha in response to doxorubicin［J］. Cancer Res, 2013, 73(20): 6230-6242. DOI: 10.1158/0008-5472.CAN-12-1345. ［15］ Liang Y, Zheng T, Song R, et al. Hypoxiamediated sorafenib resistance can be overcome by EF24 through Von HippelLindau tumor suppressordependent HIF1alpha inhibition in hepatocellular carcinoma［J］. Hepatology, 2013, 57(5): 1847-1857. DOI: 10.1002/hep.26224. ［16］ Liu Y, Zhang JB, Qin Y, et al. PROX1 promotes hepatocellular carcinoma metastasis by way of upregulating hypoxiainducible factor 1alpha expression and protein stability［J］. Hepatology, 2013, 58(2): 692705. DOI: 10.1002/hep.26398. ［17］ Li J, Xu Y, Long XD, et al. Cbx4 governs HIF1alpha to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity［J］. Cancer Cell, 2014, 25(1): 118-131. DOI: 10.1016/j.ccr.2013.12.008. ［18］ Khoo KH, Verma CS, Lane DP. Drugging the p53 pat hway: understanding the route to clinical efficacy［J］. Nat Rev Drug Discov, 2014, 13(3): 217-236. DOI: 10.1038/nrd4236. ［19］ He X, Liao J, Liu F, et al. Functional repair of p53 mutation in colorectal cancer cells using transsplicing［J］. Oncotarget, 2015, 6(4): 2034-2045. DOI: 10.18632/oncotarget.2988. ［20］ Gamell C, Jan Paul P, Haupt Y, et al. PML tumour suppression and beyond: therapeutic implications［J］. FEBS Lett, 2014, 588(16): 2653-2662. DOI: 10.1016/j.febslet.2014.02.007. ［21］ Liu ZM, Tseng JT, Hong DY, et al. Suppression of TGinteracting factor sensitizes arsenic trioxideinduced apoptosis in human hepatocellular carcinoma cells［J］. Biochem J, 2011, 438(2): 349-358. DOI: 10.1042/BJ20101653. ［22］ Guo XL, Li D, Sun K, et al. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma［J］. J Mol Med (Berl), 2013, 91(4): 473483. DOI: 10.1007/s00109-012-0966-0. ［23］ Cojoc M, Mabert K, Muders MH, et al. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms［J］. Semin Cancer Biol, 2015, 31: 1627. DOI: 10.1016/j.semcancer.2014.06.004. ［24］ Rangwala F, Williams KP, Smith GR, et al. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines［J］. BMC Cancer, 2012, 12(9): 402-412. DOI: 10.1186/1471-2407-12-402. ［25］ Hernanda PY, PedrozaGonzalez A, van der Laan LJ, et al. Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma［J］. Carcinogenesis, 2013, 34(10):2330-2340. DOI: 10.1093/carcin/bgt210. ［26］ He J, Wang M, Jiang Y, et al. Chronic arsenic exposure and angiogenesis in human bronchial epithelial cells via the ROS/miR-199a 5p/HIF-1alpha/COX-2 pathway［J］. Environ Health Perspect, 2014, 122(3): 255261. DOI: 10.1289/ehp.1307545. ［27］ Subbarayan PR, Ardalan B. In the war against solid tumors arsenic trioxide needs partners［J］. J Gastrointest Cancer, 2014, 45(3): 363-371. DOI: 10.1007/s12029-014-9617-8. ［28］ Liu B, Huang JW, Li Y, et al. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a singleblind, randomized trial［J］. J Cancer Res Clin Oncol, 2015, 141(6): 1103-1108. DOI: 10.1007/s00432-014-1866-1.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.